RAPT Therapeutics Company Insiders

RAPT Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.5135) % which means that it has lost $0.5135 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8537) %, meaning that it created substantial loss on money invested by shareholders. RAPT Therapeutics' management efficiency ratios could be used to measure how well RAPT Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.51 in 2026. Return On Capital Employed is likely to drop to -0.86 in 2026. Total Current Liabilities is likely to gain to about 58.4 M in 2026, whereas Liabilities And Stockholders Equity is likely to drop slightly above 165.3 M in 2026. Common Stock Shares Outstanding is likely to drop to about 3.9 M in 2026. Net Loss is likely to drop to about (79.2 M) in 2026RAPT Therapeutics owns a total of 28.96 Million outstanding shares. Over half of RAPT Therapeutics' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the entity is less than the current market value, you may not be able to make money on it. Dividend Paid And Capex Coverage Ratio is likely to gain to -745.92 in 2026. Common Stock Shares Outstanding is likely to drop to about 3.9 M in 2026. Net Loss is likely to drop to about (79.2 M) in 2026.

RAPT Therapeutics Workforce Comparison

RAPT Therapeutics Insider Trading History

RAPT Therapeutics Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as RAPT Therapeutics often depends on how effective the management is. RAPT Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of RAPT management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the RAPT management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in RAPT Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of RAPT Therapeutics. Check RAPT Therapeutics' Beneish M Score to see the likelihood of RAPT Therapeutics' management manipulating its earnings.

When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.